Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer-Reference-Cited by-同舟云学术

Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer

Published:2013-02-14 Issue:4 Volume:108 Page:766-770
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Heinemann V,Ebert M P,Laubender R P,Bevan P,Mala C,Boeck S

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc201362.pdf

Reference14 articles.

1. Ali SM, Marx JH, Leitzel K, Carney W, Hamer P, Linnartz R, Mietlowski W, Demers L, Harvey HA, Lipton A (2004) Pretreatment serum uPA and survival in patients with advanced pancreatic cancer. J Clin Oncol 22 (14S): ): abstract no. 4247

2. Alonso DF, Farias EF, Ladeda V, Davel L, Puricelli L, Bal de Kier Joffé E (1996) Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. Breast Cancer Res Treat 40 (3): 209–223

3. Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, Haque W, Hobbs BD, Krishnan S, Fleming JB, Das P, Lee JE, Abbruzzese JL, Wolff RA (2011) Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 29 (22): 3037–3043

4. Heinemann V, Haas M, Boeck S (2012) Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev 38 (7): 843–853

5. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P, Herman JM, Cameron JL, Yeo CJ, Halushka MK, Eshleman JR, Raben M, Klein AP, Hruban RH, Hidalgo M, Laheru D (2009) DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27 (11): 1806–1813

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PAI-1 deficiency drives pulmonary vascular smooth muscle remodeling and pulmonary hypertension;American Journal of Physiology-Lung Cellular and Molecular Physiology;2024-09-01

2. The trend toward more target therapy in pancreatic ductal adenocarcinoma;Expert Review of Anticancer Therapy;2024-05-23

3. Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts;Cancers;2024-03-05

4. Upamostat: a serine protease inhibitor for antiviral, gastrointestinal, and anticancer indications;Expert Opinion on Investigational Drugs;2023-11-23

5. A novel genetically-encoded bicyclic peptide inhibitor of human urokinase-type plasminogen activator with better cross-reactivity toward the murine orthologue;Bioorganic & Medicinal Chemistry;2023-11